Integrated Filing — IndAS


General information about company

Scrip Code 539268
NSE Symbol SYNGENE
MSEI Symbol NOTLISTED
ISIN INE398R01022
Name of company SYNGENE INTERNATIONAL LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 23-Apr-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 08-Apr-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Contract Research and Manufacturing Services
Start date and time of board meeting 23-Apr-2025   12:00:00
End date and time of board meeting 23-Apr-2025   17:30:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2025-01-23
Indicate Company website link for updated RPT policy of the Company https://cdn.syngeneintl.com/2025/02/12161216/Syngene-Policy-on-dealing-with-RPT-Amended-2025.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
There has been no default on loans and debt securities.



Financial Results Ind-AS

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 9484000000 33733000000
Other income 184000000 705000000
Total income 9668000000 34438000000
2 Expenses
(a) Cost of materials consumed 2128000000 8683000000
(b) Purchases of stock-in-trade 0 0
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 70000000 171000000
(d) Employee benefit expense 2094000000 8417000000
(e) Finance costs 101000000 312000000
(f) Depreciation, depletion and amortisation expense 896000000 3673000000
(f) Other Expenses
1 Other Expenses 2056000000 7273000000
2 Foreign exchange fluctuation loss/ (gain), net 36000000 13000000
Total other expenses 2092000000 7286000000
Total expenses 7381000000 28542000000
3 Total profit before exceptional items and tax 2287000000 5896000000
4 Exceptional items 0 320000000
5 Total profit before tax 2287000000 6216000000
6 Tax expense
7 Current tax 413000000 1197000000
8 Deferred tax 130000000 339000000
9 Total tax expenses 543000000 1536000000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations 1744000000 4680000000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period 1744000000 4680000000
17 Other comprehensive income net of taxes 597000000 -81000000
18 Total Comprehensive Income for the period 2341000000 4599000000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 4025000000 4025000000
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve 42364000000
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 4.34 11.64
Diluted earnings (loss) per share from continuing operations 4.33 11.63
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 4.34 11.64
Diluted earnings (loss) per share from continuing and discontinued operations 4.33 11.63
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 19941000000
Capital work-in-progress 8754000000
Investment property 343000000
Goodwill 0
Other intangible assets 2128000000
Intangible assets under development 47000000
Biological assets other than bearer plants 0
Investments accounted for using equity method 0
Non-current financial assets
Non-current investments 8701000000
Trade receivables, non-current 0
Loans, non-current 0
Other non-current financial assets 2094000000
Total non-current financial assets 10795000000
Deferred tax assets (net) 299000000
Other non-current assets 1423000000
Total non-current assets 43730000000
2 Current assets
Inventories 1503000000
Current financial asset
Current investments 5979000000
Trade receivables, current 4694000000
Cash and cash equivalents 2335000000
Bank balance other than cash and cash equivalents 4190000000
Loans, current 0
Other current financial assets 926000000
Total current financial assets 18124000000
Current tax assets (net) 0
Other current assets 712000000
Total current assets 20339000000
3 Non-current assets classified as held for sale 0
4 Regulatory deferral account debit balances and related deferred tax Assets 0
Total assets 64069000000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 4025000000
Other equity 42364000000
Total equity attributable to owners of parent 46389000000
Non controlling interest
Total equity 46389000000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
Total Trade payable
Other non-current financial liabilities 1802000000
Total non-current financial liabilities 1802000000
Provisions, non-current 404000000
Deferred tax liabilities (net)
Deferred government grants, Non-current 0
Other non-current liabilities 2188000000
Total non-current liabilities 4394000000
Current liabilities
Current financial liabilities
Borrowings, current 1025000000
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 295000000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 3170000000
Total Trade payable 3465000000
Other current financial liabilities 932000000
Total current financial liabilities 5422000000
Other current liabilities 7159000000
Provisions, current 665000000
Current tax liabilities (Net) 40000000
Deferred government grants, Current 0
Total current liabilities 13286000000
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 17680000000
Total equity and liabilites 64069000000
Disclosure of notes on assets and liabilities



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified to profit or loss 64000000 28000000
Total Amount of items that will not be reclassified to profit and loss 64000000 28000000
2 Income tax relating to items that will not be reclassified to profit or loss 19000000 9000000
3 Amount of items that will be reclassified to profit and loss
1 Items that will be reclassified to profit or loss 739000000 -143000000
Total Amount of items that will be reclassified to profit and loss 739000000 -143000000
4 Income tax relating to items that will be reclassified to profit or loss 187000000 -43000000
5 Total Other comprehensive income 597000000 -81000000



Cash flow statement, indirect

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 2024-04-01
B Date of end of reporting period 2025-03-31
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 6216000000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 312000000
Adjustments for decrease (increase) in inventories 861000000
Adjustments for decrease (increase) in trade receivables, current -497000000
Adjustments for decrease (increase) in trade receivables, non-current 0
Adjustments for decrease (increase) in other current assets 102000000
Adjustments for decrease (increase) in other non-current assets -39000000
Adjustments for other financial assets, non-current 0
Adjustments for other financial assets, current 0
Adjustments for other bank balances 0
Adjustments for increase (decrease) in trade payables, current 920000000
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities 1130000000
Adjustments for increase (decrease) in other non-current liabilities -201000000
Adjustments for depreciation and amortisation expense 3673000000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for provisions, current 0
Adjustments for provisions, non-current 0
Adjustments for other financial liabilities, current 0
Adjustments for other financial liabilities, non-current 0
Adjustments for unrealised foreign exchange losses gains 0
Adjustments for dividend income 0
Adjustments for interest income 550000000
Adjustments for share-based payments 302000000
Adjustments for fair value losses (gains) 0
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow 0
Other adjustments to reconcile profit (loss) 0
Other adjustments for non-cash items -76000000
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) 5937000000
Net cash flows from (used in) operations 12153000000
Dividends received 0
Interest paid 0
Interest received 0
Income taxes paid (refund) 1015000000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities 11138000000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 0
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 4336000000
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 0
Purchase of property, plant and equipment 3693000000
Proceeds from sales of investment property 0
Purchase of investment property 0
Proceeds from sales of intangible assets 0
Purchase of intangible assets 86000000
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 0
Purchase of other long-term assets 0
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 0
Interest received 498000000
Income taxes paid (refund) 0
Other inflows (outflows) of cash -487000000
Net cash flows from (used in) investing activities -8104000000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 5000000
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 0
Repayments of borrowings 417000000
Payments of lease liabilities 317000000
Dividends paid 503000000
Interest paid 133000000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) financing activities -1365000000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 1669000000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents 1669000000
Cash and cash equivalents cash flow statement at beginning of period 666000000
Cash and cash equivalents cash flow statement at end of period 2335000000







Details of Impact of Audit Qualification

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 BSR & Co. LLP Yes 31-Jul-2025


Financial details

Sr. Particulars Audited Figures (as reported before adjusting for qualifications) Adjusted Figures (audited figures after adjusting for qualifications)
1 Turnover / Total income
2 Total Expenditure
3 Net Profit/(Loss)
4 Earnings Per Share
5 Total Assets
6 Total Liabilities
7 Net Worth




Signatories detail

Name of CEO / Managing director
Name of CFO
Name of audit committee chairman
Name of statutory auditor
Name of other signatory, if any, with designation
Place
Date



Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity /subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Syngene International Limited Kiran Mazumdar Shaw Non-Executive Chairperson Any other transaction Sitting fees & Commission No remarks by the Audit Committee 4480000 0 0
2 Syngene International Limited Nilanjan Roy Independent Director Any other transaction Sitting fees & Commission No remarks by the Audit Committee 3020000 0 0
3 Syngene International Limited Manja Boerman Independent Director Any other transaction Sitting fees & Commission No remarks by the Audit Committee 2760000 0 0
4 Syngene International Limited Professor Catherine Rosenberg Non-Executive Director Any other transaction Sitting fees & Commission No remarks by the Audit Committee 3200000 0 0
5 Syngene International Limited Dr. Vijay Kuchroo Independent Director Any other transaction Sitting fees & Commission No remarks by the Audit Committee 2850000 0 0
6 Syngene International Limited Vinita Bali Independent Director Any other transaction Sitting fees & Commission No remarks by the Audit Committee 3020000 0 0
7 Syngene International Limited Sharmila Karve Independent Director Any other transaction Sitting fees & Commission No remarks by the Audit Committee 3200000 0 0
8 Syngene International Limited Kush Parmar Independent Director Any other transaction Sitting fees & Commission No remarks by the Audit Committee 2500000 0 0
9 Syngene International Limited Jonathan Hunt MD and CEO Remuneration No remarks by the Audit Committee 37000000 0 0
10 Syngene International Limited Sibaji Biswas Chief Financial Officer Remuneration No remarks by the Audit Committee 11000000 0 0
11 Syngene International Limited Deepak Jain Chief Financial Officer Remuneration No remarks by the Audit Committee 13000000 0 0
12 Syngene International Limited Priyadarshini Mahapatra Company Secretary Remuneration No remarks by the Audit Committee 4000000 0 0
13 Syngene International Limited Biocon Limited Holding Company Sale of goods or services 35000000 No remarks by the Audit Committee 17000000 0 21000000
14 Syngene International Limited Bicara Therapeutics Inc. Associate of Holding Company Sale of goods or services 1100000000 No remarks by the Audit Committee 815000000 54840000 -138000000
15 Syngene International Limited Biocon Biologics UK Limited Fellow subsidiary Sale of goods or services 70000000 No remarks by the Audit Committee 63000000 29610000 26000000
16 Syngene International Limited Biocon Biologics Limited Fellow subsidiary Sale of goods or services 20000000 No remarks by the Audit Committee 20000000 6140000 99000000
17 Syngene International Limited Biocon SDN BHD Fellow subsidiary Sale of goods or services 10000000 No remarks by the Audit Committee 6000000 0 6000000
18 Syngene International Limited Biocon Pharma Limited Fellow subsidiary Sale of goods or services 50000000 No remarks by the Audit Committee 37000000 3950000 15000000
19 Syngene International Limited Narayana Hrudayalaya Limited Enterprise in which a Director of the Company is a member of the Board of Directors Sale of goods or services 5000000 No remarks by the Audit Committee 0 0 0
20 Syngene International Limited Immuneel Therapeutics Private Limited Enterprise in which a Director of the Company is a member of the Board of Directors Sale of goods or services 5000000 No remarks by the Audit Committee 2000000 0 2000000
21 Syngene International Limited Syngene Scientific solutions Ltd. Wholly Owned Subsidiary Sale of goods or services 200000000 No remarks by the Audit Committee 67000000 74000000 38000000
22 Syngene International Limited Biosimilar collaborations Ireland Fellow subsidiary Sale of goods or services 7000000 No remarks by the Audit Committee 2000000 0 2000000
23 Syngene International Limited Cage Therapeutics Incorporation Enterprise in which a Director of the Company is a member of the Board of Directors Sale of goods or services 5000000 No remarks by the Audit Committee 0 1320000 3000000
24 Syngene International Limited Biocon Biologics Limited Fellow subsidiary Sale of goods or services 330000000 No remarks by the Audit Committee 319000000 50300000 0
25 Syngene International Limited Syngene Scientific solutions Ltd. Wholly Owned Subsidiary Sale of goods or services 1000000 No remarks by the Audit Committee 0 0 0
26 Syngene International Limited Syngene Manufacturing solutions Ltd. Wholly Owned Subsidiary Sale of goods or services 1000000 No remarks by the Audit Committee 0 0 0
27 Syngene International Limited Biocon Biologics Limited Fellow subsidiary Sale of goods or services 90000000 No remarks by the Audit Committee 84000000 29360000 0
28 Syngene International Limited Biocon Limited Holding Company Any other transaction Expenses reimbursement receivable 10000000 No remarks by the Audit Committee 3000000 0 0
29 Syngene International Limited Biocon Biologics Limited Fellow subsidiary Any other transaction Expenses reimbursement receivable 20000000 No remarks by the Audit Committee 12000000 1030000 0
30 Syngene International Limited Syngene USA Inc. Wholly Owned Subsidiary Any other transaction Expenses reimbursement receivable 80000000 No remarks by the Audit Committee 71000000 57340000 130000000
31 Syngene International Limited Syngene Scientific solutions Ltd. Wholly Owned Subsidiary Any other transaction Expenses reimbursement receivable 300000000 No remarks by the Audit Committee 164000000 26690000 0
32 Syngene International Limited Syngene USA Inc. Wholly Owned Subsidiary Any other transaction Expenses reimbursement receivable 10000000 No remarks by the Audit Committee 9000000 0 0
33 Syngene International Limited Syngene Manufacturing solutions Ltd. Wholly Owned Subsidiary Any other transaction Expenses reimbursement receivable 10000000 No remarks by the Audit Committee 0 -30000 0
34 Syngene International Limited Syngene Scientific solutions Ltd. Wholly Owned Subsidiary Any other transaction Remittance of trade receivable realized 209000000 No remarks by the Audit Committee 41000000 0 0
35 Syngene International Limited Syngene Scientific solutions Ltd. Wholly Owned Subsidiary Any other transaction Payment to vendors, bonus to employees 50000000 No remarks by the Audit Committee 23000000 0 0
36 Syngene International Limited Syngene Scientific solutions Ltd. Wholly Owned Subsidiary Any other transaction Sale of fixed assets 200000000 No remarks by the Audit Committee 0 0 0
37 Syngene International Limited Syngene Scientific solutions Ltd. Wholly Owned Subsidiary Any other transaction Purchase of fixed assets 200000000 No remarks by the Audit Committee 0 0 0
38 Syngene International Limited Biocon Limited Holding Company Any other transaction Expenses reimbursement payable 245000000 No remarks by the Audit Committee 245000000 -94090000 -139000000
39 Syngene International Limited Biocon Biologics Limited Fellow subsidiary Purchase of goods or services 270000000 No remarks by the Audit Committee 138000000 -3170000 -38000000
40 Syngene International Limited Biocon Pharma Limited Fellow subsidiary Any other transaction Expenses reimbursement payable 5000000 No remarks by the Audit Committee 2000000 -1550000 0
41 Syngene International Limited Immuneel Therapeutics Pvt Ltd. Enterprise in which a Director of the Company is a member of the Board of Directors Any other transaction Expenses reimbursement payable 5000000 No remarks by the Audit Committee 0 0 0
42 Syngene International Limited Biocon Biologics Limited Fellow subsidiary Purchase of goods or services 2000000 No remarks by the Audit Committee 0 0 0
43 Syngene International Limited Syngene Scientific solutions Ltd. Wholly Owned Subsidiary Purchase of goods or services 360000000 No remarks by the Audit Committee 354000000 -56940000 -134000000
44 Syngene International Limited Biocon Limited Holding Company Purchase of goods or services 305000000 No remarks by the Audit Committee 219000000 -15550000 -2000000
45 Syngene International Limited Biocon Limited Holding Company Purchase of goods or services 160000000 No remarks by the Audit Committee 88000000 13640000 0
46 Syngene International Limited Biocon Academy CSR related Any other transaction CSR 15000000 No remarks by the Audit Committee 14000000 1050000 0
47 Syngene International Limited Biocon Foundation Trust in which a director is a trustee Any other transaction CSR 100000000 No remarks by the Audit Committee 88000000 0 3000000
48 Syngene International Limited Syngene USA Inc. Wholly Owned Subsidiary Purchase of goods or services 1000000000 No remarks by the Audit Committee 959000000 -110060000 -48000000
49 Syngene International Limited Syngene USA Inc. Wholly Owned Subsidiary Any other transaction Business support service 344000000 No remarks by the Audit Committee 340000000 0 0
50 Syngene International Limited Syngene USA Inc. Wholly Owned Subsidiary Any other transaction Remittance of perquisite tax on exercise of ESOP 16000000 No remarks by the Audit Committee 14000000 0 0
51 Syngene International Limited Narayana Hrudayalaya Limited Enterprise in which a Director of the Company is a member of the Board of Directors Purchase of goods or services 6000000 No remarks by the Audit Committee 4000000 0 0
52 Syngene International Limited SOTC Travel Limited Enterprise in which a Director of the Company is a member of the Board of Directors of Holding Company Purchase of goods or services 55000000 No remarks by the Audit Committee 52000000 -4890000 -5000000
53 Syngene International Limited Thomas Cook (India) Limited Enterprise in which a Director of the Company is a member of the Board of Directors Purchase of goods or services 15000000 No remarks by the Audit Committee 0 0 0
54 Syngene International Limited Jeeves Enterprise in which a Director of the Company is a member of the Board of Directors Any other transaction Laundry service 5000000 No remarks by the Audit Committee 4000000 -360000 0
55 Syngene International Limited BIOSIMILARS NEWCO LIMITED Fellow subsidiary Sale of goods or services 2000000 No remarks by the Audit Committee 2000000 0 0
Total value of transaction during the reporting period 4368030000





Format for Disclosing Outstanding Default on Loans and Debt Securities

Sr. No. Particulars Amount Remarks
1. Loans / revolving facilities like cash credit from banks / financial institutions
A Total amount outstanding as on date
B Of the total amount outstanding, amount of default as on date
2. Unlisted debt securities i.e. NCDs and NCRPS
A Total amount outstanding as on date
B Of the total amount outstanding, amount of default as on date
3. Total financial indebtedness of the listed entity including short-term and long-term debt